Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Abbott to Acquire Solvay Pharmaceuticals for $6.6 Billion

Abbott Laboratories (Abbott Park, IL) agreed to acquire the pharmaceutical business of the Solvay Group (Brussels, Belgium) for EUR 4.5 billion ($6.6 billion) in cash, according to an Abbott press release.

Abbott Laboratories (Abbott Park, IL) agreed to acquire the pharmaceutical business of the Solvay Group (Brussels, Belgium) for EUR 4.5 billion ($6.6 billion) in cash, according to an Abbott press release. The transaction also includes payments of up to EUR 300 million ($437 million) if certain sales milestones are met between 2011 and 2013. Abbott will also assume certain liabilities, mainly pensions, valued at EUR 400 million ($583 million), according to a Solvay press release.

"The acquisition of Solvay Pharmaceuticals further diversifies our pharmaceutical portfolio, expands our presence in key high-growth emerging markets, enhances our investment in R&D and accelerates our long-term earnings-per-share growth outlook," said Miles D. White, chairman and chief executive officer of Abbott, in the company’s release.

Solvay Pharmaceuticals posted 2008 sales of EUR 2.7 billion ($3.9 billion), according to the Solvay press release. It employs 9000 people worldwide. Its key areas of therapeutic focus are neuroscience, cardiometabolic, influenza vaccines, gastroenterology, and men's and women's health. The acquisition also includes full global rights to the fenofibrate franchise. Currently Abbott has US rights to fenofibrate and pays royalties to Solvay. Solvay also has a small molecular diagnostics unit that will become part of Abbott's diagnostics organization upon the close of the transaction. This transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the first quarter of 2010.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content